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a  b  s  t  r  a  c  t
Acute  lymphoblastic  leukemia  (ALL)  is  a malignant  tumor  common  in  children.  Studies  of  genetic  suscep-
tibility  to cancer  using  biallelic  insertion/deletion  (INDEL)  type polymorphisms  associated  with  cancer
development  pathways  may  help  to clarify  etymology  of  ALL.  In  this  study,  we  investigate  the role  of eight
functional  INDEL  polymorphisms  and inﬂuence  of  genetic  ancestry  to  B-cell  ALL  susceptibility  in  children
of Brazilian  Amazon  population,  which  has  a high  degree  of  inter-ethnic  admixture.  Ancestry  analysis
was  estimated  using  a  panel  of  48  autosomal  ancestry  informative  markers.  130 B-cell  ALL  patients  and
125 healthy  controls  were  included  in  this  study.  The  odds  ratios  and  95%  conﬁdence  intervals  were
adjusted  for  confounders.  The  results  indicated  an  association  between  the  investigated  INDEL  polymor-
phisms  in CASP8  (rs3834129),  CYP19A1  (rs11575899)  e XRCC1  (rs3213239)  genes  in the  development
of  B-cell  ALL.  The  carriers  of Insertion/Insertion  (Ins/Ins)  genotype  of  the  polymorphism  in  CASP8  gene
presented  reduced  chances  of  developing  B-cell  ALL  (P  = 0.001;  OR = 0.353;  95%  CI  = 0.192–0.651).  The
Deletion/Deletion  (Del/Del)  genotype  of  the polymorphism  in CYP19A1  gene  was  associated  to a  lower
chance  of developing  B-cell  ALL (P =  3.35 ×  10−6;  OR  =  0.121;  95%  CI  = 0.050–0.295),  while  Del/Del  geno-
type  of  the  polymorphism  in XRCC1  gene  was  associated  to  a higher  chance  of  developing  B-cell  ALL
(P  = 2.01  × 10−4; OR = 6.559;  95%  CI  = 2.433–17.681).  We  also  found  that  Amerindian  ancestry  correlates
with the  risk  of B-cell  ALL. For  each  increase  of 10%  in the Amerindian  ancestry  results  in  1.4-fold  chances
of  developing  B-cell  ALL  (OR  =  1.406;  95%  IC = 1.123–1.761),  while  each  increase  of 10%  in the  European
ancestry  presents  a protection  effect  in  the  development  of  B-cell  ALL  (OR  =  0.666;  95% IC = 0.536–0.827).
The  results  suggest  that genetic  factors  inﬂuence  leukemogenesis  and  might  be explored  in the  stratiﬁ-
cation  of  B-cell  ALL  risk  in admixed  populations.
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. Introduction
Acute lymphoblastic leukemia (ALL) is a malignant tumor com-
on  in children that accounts for more than 30% of all pediatric
ancers [1]. Despite many studies, ALL etiology is not well deﬁned.
arious studies have suggested that an interaction between expo-
ure to certain environmental agents and genetic susceptibility has
n important mechanistic role in the development of this childhood
eukemia [2–4]. In this context, studies of genetic susceptibility
o cancer using biallelic insertion/deletion (INDEL)-type polymor-
hisms associated with cancer development pathways may  help to
larify the etiology of a certain tumor [5–7]. Polymorphisms of the
NDEL type have been related to susceptibility to different cancers,
ncluding gastric [8,9], breast [10–12], colorectal [13–15] and oth-
rs [16,17]. However, studies linking INDEL type polymorphisms
nd susceptibility to ALL are scarce [18].
To provide a more complete view of ALL etiology, we  selected
ight polymorphisms in genes (CYP2E1, CYP19A1, TYMS, XRCC1,
P53, CASP8, NFKˇ1 and IL-1˛) involved in pathways associated
o the carcinogenesis of different types of cancer, including B-cell
cute lymphoblastic leukemia (B-cell ALL) [19]. These genes encode
nzymes of the carcinogens metabolism [20–22], enzymes of the
olate metabolism [23–25] and proteins of DNA repair [26–28],
poptosis and immune response [29–31].
Furthermore, it is well reported in the literature that ethnic dif-
erences inﬂuence in ALL incidence [32–35]. Children with admixed
ncestry, such as Hispanic, tend to have a greater risk of develop-
ng B-cell ALL in comparison to children from other ethnic groups
35]. This higher incidence in Hispanic children is, at least partially,
ttributable to genomic variations that are characteristic of Native
merican genetic ancestry [36]. Therefore, it is conceivable that
enomic variations related to ancestry may  contribute to ethnic dis-
arities in ALL incidence. This is especially important in admixed
opulations, such as the Brazilian, which is known for being one
f the most heterogeneous populations worldwide, with the main
ontribution of three parental groups: Amerindian, European and
frican [37,38]. However, there are no works exploring the inﬂu-
nce of genetic ancestry in the risk of developing ALL in Brazilian
hildren.
The goal of this work was to investigate the role of eight func-
ional INDEL polymorphisms and the inﬂuence of genetic ancestry
n B-cell acute lymphoblastic leukemia susceptibility in children
rom an Amazon region with high degree of inter-ethnic admixture.
. Materials and methods
.1. Cases and controls
The research participants were chosen based on a case-control
tudy design. The case group was composed of B-cell acute lym-
hoblastic leukemia patients (n = 130) in treatment for childhood
ancer in the clinics of the Hospital Ophir Loyola (Pará, Brazil)
etween the years of 2006 and 2012. Samples from 125 non-related
ancer-free individuals from the same geographic area were used
s controls.
All patients included in the study were conﬁrmed to have
cute lymphoblastic leukemia based on the criteria of the French-
merican-British (FAB) rating systems. Samples of bone marrow or
eripheral blood were obtained at the time of diagnosis. Immuno-
henotype was determined for ALL cases using ﬂow cytometry
roﬁles, as previously described [39].earch 39 (2015) 1239–1245
2.2. Ethical aspects
The protocol used in this study was approved by the Com-
mittee for Research Ethics of the Universidade Federal do Pará
(UFPA; approval no. 119.649). Consent forms were obtained from
all patients and control participants in the study.
2.3. DNA extraction and quantiﬁcation
Genomic DNA was extracted using a commercial kit for DNA
extraction (Roche Applied Science DNA Isolation Kit, Penzberg,
Germany) and quantiﬁed with a NanoDrop 1000 spectrophotome-
ter (Thermo Scientiﬁc NanoDrop 1000; NanoDrop Technologies,
Wilmington, DE).
2.4. Analysis of polymorphisms
Multiplex polymerase chain reaction (PCR) was used to allow
the simultaneous ampliﬁcation of eight investigated markers (Sup-
plemental material, Table A).
Ampliﬁcation of the markers was performed on an ABI Verity
thermocycler (Life Technologies, Foster City, CA, USA). The PCR-
based genotyping assay used a QIAGEN Multiplex PCR kit (QIAGEN,
Germany) with the following reaction conditions: 5.0 L of QIAGEN
Multiplex PCR Master Mix, 1.0 L of Q-solution, 1.0 L of Primer
Mix, 2.0 L of water, and 1.0 L of DNA. The samples were incu-
bated at 95 ◦C for 15 min, followed by 35 cycles of 94 ◦C for 45 s,
60 ◦C for 90 s and 72 ◦C for 1 min, with a ﬁnal extension at 70 ◦C
for 30 min. For fragment analysis using capillary electrophoresis,
1.0 L of PCR product was added to 8.5 L of HI-DI deionized form-
amide (Life Technologies) and 0.5 L of GeneScan 500 LIZ pattern
size standard (Life Technologies). DNA fragments were separated
using the ABI PRISM 3130 genetic analyzer (Life Technologies) and
analyzed using the GeneMapper ID v.3.2 software (Life Technolo-
gies).
2.5. Analysis of ancestral populations
The INDEL polymorphisms here investigated that presented
genotypic distribution signiﬁcantly different between cases and
controls were investigated in a sample of 703 individuals from
different continents, including: 270 European individuals (mainly
Portuguese individuals), 211 Sub-Saharan Africans (individuals
from Angola, Mozambique, Zaire, Cameroon and the Ivory Coast)
and 222 Native American individuals (from indigenous tribes of
the Brazilian Amazon region). Details about these populations can
be found in [37].
2.6. Analysis of genetic ancestry
Ancestry analysis was performed according to Santos et al. [37]
using 48 autosomal ancestry informative markers (AIMs). Three
multiplex PCR reactions with 16 markers each were performed,
and the PCR amplicons were analyzed by electrophoresis using
the ABI Prism 3130 sequencer and GeneMapper ID v.3.2 software.
The individual proportions of European, African and Amerindian
genetic ancestries were estimated using STRUCTURE v.2.3.3 soft-
ware, assuming three parental populations (European, African and
Amerindian).
2.7. Statistical analysisAll statistical analyses were performed using SPSS v.20.0 Sta-
tistical Program (SPSS, Chicago, IL, USA). Group comparisons for
the categorical variables (gender) were tested in pairs by Pearson’s
Chi-squared test, while Student’s t-test was used for the analysis of
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Table  1
Demographic variables for patients with B-cell ALL and the control group.
Variable Case Control P-value
No. 130 125
Age, yearsa 5.16 ± 2.79 23.09 ± 4.62 0.006
Gender (male/female) 85/45 55/70 0.001
Genetic ancestryb
European ancestry 0.443 ± 0.115 0.505 ± 0.131 2.42 × 10−5
African ancestry 0.218 ± 0.904 0.204 ± 0.790 0.291
Amerindian ancestry 0.339 ± 0.116 0.294 ± 0.119 2.92 × 10−4
aValues are as expressed as mean (±SD = standard deviation). Signiﬁcance deter-
mined by Student’s t-test.
bValues are as expressed as mean ± SD. Signiﬁcance determined by Mann–Whitney
test.
Table 2
Categorical distribution of Amerindian and European ancestry in patients with B-cell
ALL in the comparison with the control group.
Genetic Ancestry (%) Case no. (%) Control no. (%)
Amerindian ancestry
[5–10] 1 (1) 3 (2)
[10–20] 18 (14) 25 (20)
[20–30] 30 (23) 47 (38)
[30–40] 44 (34) 30 (24)
[40–50] 22 (17) 10 (8)
[50–60] 12 (9) 10 (8)
>60 3 (2) 0
P-value 0.010
European ancestry
[5–10] 1 (1) 3 (2)
[10–20] 3 (2) 2 (1)
[20–30] 13 (10) 7 (6)
[30–40] 30 (23) 17 (14)
[40–50] 45 (35) 27 (22)
[50–60] 26 (20) 38 (30)
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s>60 12 (9) 31 (25)
P-value 0.001
uantitative variables (age). For the comparison of ancestry index
mong the samples, we used Mann-Whitney test. Multiple logis-
ic regression analyses were carried out to estimate odds ratios
ORs) and their 95% conﬁdence intervals (CIs). In these analyses,
ovariates considered as potential confounders (age, gender and
enetic ancestry) were analyzed. All statistical tests were based on
 two-tailed probability and P-value <0.05 was considered signiﬁ-
ant. P-values were adjusted by Bonferroni correction for multiple
esting.
. Results
.1. Demographic
We  analyzed 130 patients with B-cell ALL and 125 healthy indi-
iduals. Table 1 shows the demographic features of these groups.
he case group was predominately male, while the control group
ad a higher proportion of females. The results showed statistically
igniﬁcant differences between the cases and controls in the follow-
ng variables: age (P = 0.006), gender (P = 0.001), European ancestry
P = 2.42 × 10−5) and Amerindian ancestry (P = 2.92 × 10−4).
Regarding genomic ancestry, the ethnic composition of the
ase group was 44% European, 22% African and 34% Amerindian,
hile the control group was 50% European, 20% African and 30%
merindian. The results revealed an increased Amerindian ancestry
nd a reduced European ancestry in B-cell ALL patients compared
ith the control group.
Using 10% increments, we compared the categorical distribu-
ion of the estimated Amerindian and European ancestries in the
tudied population (Table 2), and we found different distributionsearch 39 (2015) 1239–1245 1241
of these ancestries between the case and control groups. To deter-
mine the inﬂuence of ancestry in the susceptibility to B-cell ALL, we
performed a logistic regression (Table 3). According to the adopted
model, for each increase of 10% in the Amerindian ancestry there
are 1.4-times higher chances of developing B-cell ALL (OR  = 1.406;
95% CI = 1.123–1.761), while each increase of 10% in the Euro-
pean ancestry results in reduced chances of developing B-cell ALL
(OR = 0.666; 95% CI = 0.536–0.827).
3.2. Distribution of genotypes associated with susceptibility to
ALL
The genotypic distributions of CYP2E1, CYP19A1, TYMS, XRCC1,
TP53, CASP8, NFKˇ1 and IL-1  ˛ markers in the case group compared
with the control group are described in Table 4. Analyses were per-
formed multivariate regression (adjusted for age, gender and for
European and Amerindian ethnicities). Through Bonferroni cor-
rection, P-values were corrected for eight INDEL, which was the
number of performed tests (Plimit = 0.00625).
The polymorphisms in TP53, NFKˇ1, TYMS,  CYP2E1 and IL-1˛
genes had no signiﬁcant effect in the analysis after adjustment
using multiple logistic regression.
In relation to the polymorphism in CASP8 (rs3834129) gene, the
carriers of Insertion/Insertion (Ins/Ins) genotype present dimin-
ished chances (P = 0.001; OR = 0.353; 95% CI = 0.192–0.651) in the
development of B-cell ALL. Analyses also revealed reduced chances
of developing B-cell ALL for the carriers of deletion/deletion
(Del/Del) genotype in CYP19A1 (rs11575899) gene (P = 3.35 × 10−6;
OR = 0.121; 95% CI = 0.050–0.295).
In the XRCC1 gene, a signiﬁcant risk association was  found
for the Del/Del genotype (rs3213239) (P = 2.01 × 10−4; OR  = 6.559;
95% CI = 2.433–17.681). Therefore, individuals homozygous for this
deletion in the XRCC1 gene have an approximately 7-fold increased
risk of ALL development over those with other genotypes.
4. Discussion
B-cell ALL is the most common neoplasm in children [1]. The
association of the investigated polymorphisms with the risk of
developing this type of leukemia was  studied, and demographic
factors such as gender and ancestry were used to control for possi-
ble confounding effects. ALL incidence is approximately 20% higher
in males than in females [40]. Similarly, males were predominant
among the B-cell ALL patients studied herein.
Our results show that genetic ancestry inﬂuences the risk of
developing B-cell ALL. Amerindian ancestry correlated with the risk
of developing B-cell ALL, while European ancestry had a protective
effect on the development of this childhood leukemia in the studied
population (Table 3).
Our study found genetic ancestry differences in the incidence
of ALL [36,41–44]. Our results corroborate with those of Walsh
et al. [36], in which Native American ancestry is associated with
an increased risk of B-cell ALL in Hispanic children. In that work,
each 20% increase in the proportion of an individual’s genome
that is of Native American origin conferred a 1.20-fold increased
risk of B-cell ALL. Whereas Hispanics are an admixed population
between European, African and Native American ancestries, the
authors suggested that the observed high incidence of B-cell ALL
in Hispanic children might be partially attributed to genetic risk
factors associated with Amerindian ancestry [36]. We employed a
statistical approach similar to the work of Walsh et al. [36] and
found that an increment of 10% in the Amerindian ancestry corre-
sponds to an increment of 1.4-times the risk of developing B-cell
ALL in the investigated Brazilian population. Therefore, our results
are promising because they can help to clarify leukemogenesis and
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Table  3
Odds ratio (OR) and 95% conﬁdence intervals (CIs) of logistic regression model of Amerindian and European ethnicity.
Genetic ancestry Case mean Control mean ORa 95% CIa P-valuea
Amerindian ancestry 0.339 ± 0.116 0.294 ± 0.119 1.406 1.123–1.761 0.003
European ancestry 0.443 ± 0.115 0.505 ± 0.131 0.666 0.536–0.827 2 × 10−4
Logistic regression adjusted for confounders.
a Odds-ratio of 10% ethnicity increase.
Table 4
Genotype distribution of the investigated polymorphisms in patients with B-cell ALL in comparison with the control group.
Genotype No. (%) No. (%)
Case Control P-valuea OR (95% IC)a
CASP8 130 125
INS/INS 23 (17.7) 47 (37.6) 0.001 INS/INS vs. others: 0.353 (0.192–0.651)
INS/DEL  81 (62.3) 53 (42.4)
DEL/DEL 26 (20) 25 (20)
Allele INS 0.488 0.588
Allele DEL 0.512 0.412
TYMS 130 125
INS/INS 33 (25.4) 53 (42.4) 0.005 INS/INS vs. others: 0.438 (0.247–0.775)
INS/DEL  84 (64.6) 56 (44.8)
DEL/DEL 13 (10) 16 (12.8)
Allele INS 0.577 0.648
Allele DEL 0.423 0.352
CYP19A1  130 121
INS/INS 41 (31.5) 25 (20.7)
INS/DEL 82 (63.1) 56 (46.3)
DEL/DEL 7 (5.4) 40 (33) 3.35 × 10−6 DEL/DEL vs. others: 0.121 (0.050–0.295)
Allele  INS 0.631 0.438
Allele DEL 0.369 0.562
TP53  130 125
INS/INS 2 (1.5) 6 (4.8)
INS/DEL 54 (41.5) 33 (26.4)
DEL/DEL 74 (57) 86 (68.8) 0.097 DEL/DEL vs. others: 0.630 (0.364–1.088)
Allele  INS 0.223 0.180
Allele DEL 0.777 0.820
NFK1  130 123
INS/INS 17 (13.1) 28 (22.8)
INS/DEL 74 (56.9) 49 (39.8)
DEL/DEL 39 (30) 46 (37.4) 0.202 DEL/DEL vs. others: 0.692 (0.394–1.218)
Allele  INS 0.415 0.427
Allele DEL 0.585 0.573
XRCC1  122 123
INS/INS 64 (52.4) 65 (52.8)
INS/DEL 34 (27.9) 51 (41.5)
DEL/DEL 24 (19.7) 7 (5.7) 2.01 × 10−4 DEL/DEL vs. others:6.559 (2.433–17.681)
Allele INS 0.664 0.736
Allele DEL 0.336 0.264
CYP2E1 105 123
INS/INS 4 (3.8) 2 (1.6)
INS/DEL 8 (7.6) 12 (9.8)
DEL/DEL 93 (88.6) 109 (88.6) 0.681 DEL/DEL vs. others: 1.204 (0.496–2.921)
Allele  INS 0.076 0.065
Allele DEL 0.924 0.935
IL-1  130 125
INS/INS 46 (35.4) 45 (36)
INS/DEL 69 (53.1) 55 (44)
DEL/DEL 15 (11.5) 25 (20) 0.05 DEL/DEL vs. others: 0.478 (0.229–0.995)
Allele INS 0.619 0.580
t
B
t
B
i
p
cAllele DEL 0.381 0.420
a Logistic regression adjusted for confounders
o ﬁnd biomarkers that might be of interest in the stratiﬁcation of
-cell ALL risk in admixed populations.
In the present work, we found signiﬁcant associations between
hree investigated INDEL polymorphisms and the development of
-cell ALL. Data suggest that Ins/Ins genotype of the polymorphism
n CASP8 (rs3834129) gene and Del/Del genotype of the polymor-
hism in CYP19A1 (rs11575899) gene are associated to a lower
hance of developing B-cell ALL, while Del/Del genotype of the poly-morphism in XRCC1 (rs3213239) gene is associated to a higher risk
of developing B-cell ALL.
CASP8 is a key-regulator of apoptosis, which is a defense mech-
anism that is fundamental against tumor development [5]. The
deletion of 6 bp (CTTACT), at −652 in promoter region of CASP8
gene (rs3834129) suppresses linkage site Sp1, which acts as a tran-
scription factor of the gene. Notably, this polymorphism has been
associated with the development of many types of cancer, includ-
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Table  5
Genotype distribution of the polymorphisms in the CASP8,  CYP19A1 and XRCC1 genes in patients with B-cell ALL compared with the control group and parental populations
(European, Amerindian and African).
No. (%)
Genotype Case Control European African Amerindian
CASP8 (rs3834129) 130 125 268 211 222
INS/INS 23 (17.7) 47 (37.6) 81 (30) 49 (18.1) 142 (52.6)
INS/DEL 81 (62.3) 53 (42.4) 123 (45.6) 113 (41.9) 59 (21.9)
DEL/DEL 26 (20) 25 (20) 64 (23.7) 49 (18.1) 21 (7.8)
Allele  INS 0.488 0.588 0.532 0.5 0.773
Allele  DEL 0.512 0.412 0.468 0.5 0.227
CYP19A1  (rs11575899) 130 121 270 211 222
INS/INS 41 (31.5) 25 (20.7) 85 (31.5) 95(45) 92 (41.44)
INS/DEL 82 (63.1) 56 (46.3) 145 (53.7) 97(46) 98 (44.14)
DEL/DEL 7 (5.4) 40 (33) 40 (14.8) 19 (9) 32 (14.4)
Allele  INS 0.631 0.438 0.5833 0.6801 0.6351
Allele  DEL 0.369 0.562 0.4167 0.3199 0.3649
XRCC1 (rs3213239) 122 123 261 211 222
INS/INS 64 (52.4) 65 (52.8) 117(44.8) 85 (40.3) 215 (96.8)
INS/DEL 34 (27.9) 51 (41.5) 116 (44.4) 95 (45) 5 (2.3)
DEL/DEL 24 (19.7) 7 (5.7) 28 (10.7) 31 (14.7) 2 (0.9)
Allele  INS 0.664 0.736 0.6705 0.628 0.9797
Allele  DEL 0.336 0.264 0.3295 0.372 0.0203
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Ang in lung, breast, stomach, colon/rectum, pancreas, among others
5,17]. However, there is no information over the inﬂuence of this
olymorphism to the risk of developing childhood B-cell ALL.
The CYP19A1 gene encodes the aromatase enzyme, which is
esponsible for the ﬁnal phase of estrogen biosynthesis. Thus, muta-
ions in this gene may  affect the levels of aromatase enzyme activity
s well as cellular differentiation and growth [45]. Polymorphisms
n this gene have been associated with an increased risk of breast
ancer [10,46] and gastric cancer [47]. However, little is known
bout the relationship between CYP19A1 variants and B-cell ALL
usceptibility.
The XRCC1 protein is one of the most important proteins for
ase excision repair (BER) [26–28]. This pathway is also important
o repair DNA damages caused by oxidation and alkylation [28].
olymorphic alterations in this gene have been associated with ALL
isk in infants [48–50].
We  seek to interpret the observed allelic differences for these
hree INDEL polymorphisms based on their frequencies in parental
opulations and on the ethnic contribution of the group of patients
nd control. Whereas the ethnic contribution of Amerindian in the
roup of patients higher than in the group of controls, such alleles
ould be differentially represented both in Amerindian ancestral
roup as in the group of patients in the admixed population, inde-
endent of the allele effect on the development of B-cell ALL.
ata of the analyses of ancestral populations (European, African
nd Amerindian) presented in Table 5do not favor this interpreta-
ion. On the contrary, they indicate that the observed differences
etween cases and controls, regarding polymorphisms in CASP8
rs3834129), CYP19A1 (rs11575899) and XRCC1 (rs3213239) genes,
annot be explained based on differences in contribution between
he two ethnic groups.
For the polymorphism in CASP8 (rs3834129) gene, Ins/Ins geno-
ype is underrepresented among the patients in comparison to the
ontrols and it was associated as a protection factor for B-cell ALL. In
he investigated sample of Amerindian individuals, the frequency
f Ins allele (0.77) was higher than in European (0.53) and African
0.50) individuals.For the polymorphism in CYP19A1 (rs11575899) gene, Del allele
as underrepresented in the sample of patients in comparison to
he controls and it was associated as a protection factor for B-cell
LL. In the investigated sample of Amerindian individuals, the fre-quency of this allele (0.36) is intermediate to European (0.42) and
African (0.32) individuals.
For the polymorphism in XRCC1 (rs3213239) gene, Del/Del
genotype is overrepresented in the group of patients. However, the
frequency of Del allele is greatly reduced among Amerindian (0.02)
in comparison to African (0.37) and European (0.33).
5. Conclusions
In conclusion, these data demonstrate that the investi-
gated INDEL polymorphisms in the CASP8 (rs3834129), CYP19A1
(rs11575899), and XRCC1 (rs3213239) genes, as well as Amerindian
genetic ancestry, are signiﬁcantly important for B-cell ALL suscep-
tibility in Brazilian Amazon children. To the best of our knowledge,
this is the ﬁrst study to describe the inﬂuence of these INDEL poly-
morphisms to B-cell ALL development and to associate Amerindian
genetic ancestry with the development childhood B-cell ALL in an
admixed Brazilian population.
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